IL13RA2 and neoplasm: The recent developments enabling the use of CAR-T cells targeting specific antigens, such as IL13Rα2, in conjunction with tumor lysates can enhance the effectiveness of the immune response by promoting direct interactions between modified T cells and tumor cells [125].